ARTICLE | Clinical News
Joulferon albinterferon alfa-2b regulatory update
April 26, 2010 7:00 AM UTC
Novartis withdrew an MAA for Joulferon albinterferon alfa-2b to treat chronic HCV after the European Medicines Agency (EMA) requested additional data that will require the pharma to conduct further st...